1 %

DRUG3 trials

Sponsors

Centre Hospitalier Universitaire De Nice, eyeDNA Therapeutics, Assistance Publique Hopitaux De Paris

Conditions

Acnegender dysphoriaretinitis pigmentosa

Phase 1

Safety and Efficacy of a Unilateral Subretinal Administration of HORA PDE6B in Patients with Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression

CompletedCTIS2024-511687-90-00

eyeDNA Therapeuticsretinitis pigmentosa

Start: 2017-10-12End: 2025-06-30Target: 23Updated: 2024-05-17

Phase 3

Randomized clinical trial to compare oral isotretinoin to standard of care in moderate acne skin of color patients

RecruitingCTIS2023-507519-36-00

Centre Hospitalier Universitaire De NiceAcne

Start: 2025-04-29Target: 420Updated: 2025-12-15

TRANSADO - Evaluation of the effectiveness of hormonal treatment in adolescents suffering from gender dysphoria

RecruitingCTIS2024-513250-30-00

Assistance Publique Hopitaux De Parisgender dysphoria

Start: 2024-06-25Target: 60Updated: 2025-06-12